Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally.
Suven Life Sciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹99.65|
|52 Week High||₹42.05|
|52 Week Low||₹124.40|
|1 Month Change||3.05%|
|3 Month Change||18.28%|
|1 Year Change||108.04%|
|3 Year Change||-58.87%|
|5 Year Change||-47.15%|
|Change since IPO||278.90%|
Recent News & Updates
|530239||IN Life Sciences||IN Market|
Return vs Industry: 530239 exceeded the Indian Life Sciences industry which returned 46.8% over the past year.
Return vs Market: 530239 exceeded the Indian Market which returned 62.5% over the past year.
Stable Share Price: 530239 is more volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 530239's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. It engages in drug discovery and development of new chemical entities (NCE) in central nervous system therapies. The company’s product candidates include SUVN-502 for the treatment of Alzheimer’s disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders.
Suven Life Sciences Fundamentals Summary
|530239 fundamental statistics|
Is 530239 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|530239 income statement (TTM)|
|Cost of Revenue||₹1.03m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-4.46|
|Net Profit Margin||-1,655.85%|
How did 530239 perform over the long term?See historical performance and comparison
Is Suven Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 530239's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 530239's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 530239 is unprofitable, so we can't compare its PE Ratio to the Indian Life Sciences industry average.
PE vs Market: 530239 is unprofitable, so we can't compare its PE Ratio to the Indian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 530239's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 530239 is overvalued based on its PB Ratio (50.9x) compared to the IN Life Sciences industry average (3.6x).
How is Suven Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Suven Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Suven Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 530239 is currently unprofitable.
Growing Profit Margin: 530239 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 530239 is unprofitable, and losses have increased over the past 5 years at a rate of 67.9% per year.
Accelerating Growth: Unable to compare 530239's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 530239 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.7%).
Return on Equity
High ROE: 530239 has a negative Return on Equity (-227.83%), as it is currently unprofitable.
How is Suven Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: 530239's short term assets (₹358.3M) exceed its short term liabilities (₹91.3M).
Long Term Liabilities: 530239's short term assets (₹358.3M) exceed its long term liabilities (₹37.1M).
Debt to Equity History and Analysis
Debt Level: 530239's debt to equity ratio (1.8%) is considered satisfactory.
Reducing Debt: 530239's debt to equity ratio has reduced from 12.1% to 1.8% over the past 5 years.
Debt Coverage: 530239's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 530239's interest payments on its debt are well covered by EBIT.
What is Suven Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 530239's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 530239's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 530239's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 530239's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 530239 is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 530239's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Venkat Jasti (72 yo)
Mr. Venkateswarlu Jasti, also known as Venkat, M.Pharm. M.S. serves as Chairman of the Board and Managing Director at Suven Pharmaceuticals Limited since November 06, 2019. He serves as Managing Director a...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Venkat's total compensation is reasonable compared to companies of similar size in the Indian market.
Compensation vs Earnings: Venkat's compensation has increased whilst the company is unprofitable.
Experienced Management: 530239's management team is seasoned and experienced (6.4 years average tenure).
Experienced Board: 530239's board of directors are considered experienced (7.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 100%.
Suven Life Sciences Limited's employee growth, exchange listings and data sources
- Name: Suven Life Sciences Limited
- Ticker: 530239
- Exchange: BSE
- Founded: 1989
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹25.367b
- Shares outstanding: 254.56m
- Website: https://www.suven.com
Number of Employees
- Suven Life Sciences Limited
- # 8-2-334, SDE Serene Chambers
- 6th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/27 15:39|
|End of Day Share Price||2021/10/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.